Apimeds Pharmaceuticals US Inc Dossier - Source-backed chat

Apimeds Pharmaceuticals US Inc

APUSNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.47

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.00Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $7.5M

Enterprise Value $15.9M

Shares Outstanding 1.5M diluted

Next Earnings Date15 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Apimeds Pharmaceuticals US, Inc. (APUS) presents a highly speculative, high-risk investment profile that bridges early-stage biopharmaceutical development with a volatile digital asset treasury strategy. The company's lead asset, Apitox (LT-100), is a purified honeybee venom biologic with a strong 20-year safety history in South Korea, currently targeting a confirmatory Phase 3 trial in the U.S. for knee osteoarthritis. However, the company's financial health is heavily tied to its digital asset segment (acquired via the MindWave Innovations merger in December 2025), which exposed APUS to a massive $35.1 million net loss in Q1 2026 due to unrealized cryptocurrency losses. Combined with severe governance disputes (recently settled in May 2026), delayed SEC filings, and going concern warnings, investors should maintain a Hold stance until regulatory compliance is restored and the clinical path for Apitox is fully cleared.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to file its SEC reports timely, leading to delisting from the NYSE American. The FDA demands extensive preclinical or manufacturing modifications for LT-100, delaying the Phase 3 trial indefinitely. Continued cryptocurrency market declines wipe out the treasury's value, and the company is unable to access the restricted portions of its PIPE facility, leading to insolvency.

Base CaseCentral scenario

The company successfully files its delayed 2025 Form 10-K, regaining compliance with NYSE American listing standards. The FDA Type C meeting results in a clear, agreed-upon protocol for the confirmatory Phase 3 trial of LT-100 in knee osteoarthritis. The digital asset treasury stabilizes, allowing the company to draw down on its $120.9 million PIPE facility to fund clinical operations without excessive dilution.

Bull CaseUpside scenario

Successful completion of the Phase III trial for Apitox in knee osteoarthritis, leading to FDA BLA approval and securing 12 years of biologic market exclusivity in the United States.

Scenarios reflect our research view at the research date.

Key Investment Merits

Apitox (LT-100) has a well-established 20-year safety and efficacy track record in South Korea under the brand name Apitoxin, reducing clinical safety risk.
If approved, Apitox qualifies for 12 years of U.S. biologic exclusivity under FDA regulations.
The $120.9 million PIPE facility provides a theoretical capital runway to support late-stage clinical trials if draw conditions are met.

Key Investment Risks

Extreme financial volatility driven by the company's digital asset treasury segment, which holds over $127 million in highly volatile cryptocurrencies.
Substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and restricted cash access.
Regulatory and listing risks, highlighted by the NYSE American non-compliance notice and trading halt following delayed SEC filings.

Thesis Invalidation Triggers

Delisting of APUS common stock from the NYSE American exchange.
Failure to reach an agreement with the FDA on the Phase 3 trial design for LT-100.
Inability to resolve internal control material weaknesses, leading to a qualified audit opinion on future financial statements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.